Philips extends Volcano tender offer; Velano raises $5M for phlebotomy needle alternative;

@FierceMedDev: ICYMI yesterday: Boston Scientific CEO touts pipeline during earnings call. Article | Follow @FierceMedDev

@VarunSaxena2: Boston Scientific CEO touts pipeline during earnings call. More | Follow @VarunSaxena2

@EmilyWFierce: Sen. Warren has a bone to pick with pharma, but devicemakers are getting a hall pass. More from Time | Follow @EmilyWFierce

> A top performing Israeli stock last year was skin rejuvenation device company EndyMed, which has gained more than 90% in the last year according to Reuters. Story

> Philips ($PHG) has extended the tender offer for Volcano ($VOLC) until Feb. 17 in order to satisfy Taiwanese regulators by Feb. 14. Release

> Velano Vascular has raised a $5 million Series A round to offer an alternative to phlebotomy needles. Investors include First Round Capital, White Owl Capital, Kapor Capital, Safeguard Scientifics ($SFE) as well as undisclosed angel investors and two major hospitals. Release

> U.S. Senator Elizabeth Warren introduce a bill in late January to penalize pharma companies breaking the law and create an R&D fund with the proceeds. It doesn't include medical device companies. Warren also is in support of repealing the medical device tax that helps fund the Affordable Care Act. Story

Biotech News

@FierceBiotech: G1 banks $33M to cut in on a blockbuster oncology race. News | Follow @FierceBiotech

@JohnCFierce: Look for more M&A ahead: Pfizer beefs up on biosimilars with $15B Hospira deal. Article | Follow @JohnCFierce

@DamianFierce: $AZN says it's on schedule to submit brodalumab this year and the PD-L1-blocking '4736 in 2016. Picture | Follow @DamianFierce

> Armetheon raises $24M to get its anticoagulant into Phase III. News

> FDA chief Hamburg is stepping down. Is Califf the next commissioner? More

> U.K. panel calls for innovation fund to break antibiotic discovery dam. Report

Pharma News

@FiercePharma: Scientists in search of next-generation #Ebola #vaccines as outbreak dwindles. More | Follow @FiercePharma

@EricPFierce: Hospira says it will be acquired by Pfizer for $17B. Oh and it had another recall too. News | Follow @EricPFierce

@CarlyHFierce: Measles-jab maker Merck says it can only do so much to encourage vaccination. Story | Follow @CarlyHFierce

> Look for a new Sanofi CEO by March, says chairman, as earnings top forecast. News

> FDA chief Hamburg to step down, with new deputy a potential successor. More

> AstraZeneca continues its respiratory land grab with $600M-plus Actavis deal. Article

Vaccines News

> Scientists in search of next-generation Ebola vaccines as outbreak dwindles. Item

> Measles-jab maker Merck says it can only do so much to encourage vaccination. Report

> Takeda drops DTaP/sIPV development to focus on 'higher-impact' programs. More

> Serum Institute gets Genticel's Vaxiclase tech to develop pertussis vaccine. Story

> Astellas joins forces with Immunomics on allergy vaccine. Article

Pharma Manufacturing News

> Hospira issues another recall even as Pfizer announces buyout deal. Story

> Dr. Reddy's expanding capacity at three plants. News

> India's Wockhardt says it has addressed U.S. FDA compliance issues at Illinois plant. More

> U.K. regulators shut down plant making potentially contaminated drug. Story

> Novo investing $750M in manufacturing this year. Article

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.